Current osteoporosis prevention and management

被引:0
作者
Binkley, N
Krueger, D
机构
[1] Univ Wisconsin, Wisconsin Osteoporosis Clin Ctr, Madison, WI 53705 USA
[2] Univ Wisconsin, Res Program, Madison, WI 53705 USA
关键词
fractures; osteoporosis; treatment;
D O I
暂无
中图分类号
R4 [临床医学]; R592 [老年病学];
学科分类号
1002 ; 100203 ; 100602 ;
摘要
This review presents a clinical approach to osteoporosis prevention and treatment. Initially, a medical history, including assessment of factors predisposing to bone loss, the impact of osteoporosis on activities of daily living and psychological function, physical examination, and appropriate laboratory evaluation is necessary. Subsequently, the goals of osteoporosis prevention and treatment are pain control, maximization of function, maintenance of bone mass, and fracture prevention. An individual clinician or a multidisciplinary team may meet these goals. In brief, it is essential to evaluate nutritional status with emphasis on optimization of calcium and vitamin D intake. Physical activity to maintain muscle strength and bone mass and reduce falls risk is addressed elsewhere in this issue. Use of one of the increasing armamentarium of pharmaceutical agents that preserve or increase bone mass may be indicated on the basis of bone mass and other factors. Patient education regarding osteoporosis in general, and falls risk and body mechanics in particular, plays an important role in osteoporosis prevention and treatment. Finally, controversies in the medical management of osteoporosis are addressed.
引用
收藏
页码:17 / 29
页数:13
相关论文
共 106 条
[81]  
Recker RR, 1996, J BONE MINER RES, V11, P1961
[82]   Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [J].
Reginster, JY ;
Minne, HW ;
Sorensen, OH ;
Hooper, M ;
Roux, C ;
Brandi, ML ;
Lund, B ;
Ethgen, D ;
Pack, S ;
Roumagnac, I ;
Eastell, R .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (01) :83-91
[83]   Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial [J].
Reid, DM ;
Hughes, RA ;
Laan, RFJM ;
Sacco-Gibson, NA ;
Wenderoth, DH ;
Adami, S ;
Eusebio, RA ;
Devogelaer, JP .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (06) :1006-1013
[84]   Intravenous zoledronic acid in postmenopausal women with low bone mineral density. [J].
Reid, IR ;
Brown, JP ;
Burckhardt, P ;
Horowitz, Z ;
Richardson, P ;
Trechsel, U ;
Widmer, A ;
Devogelaer, J ;
Kaufman, J ;
Jaeger, P ;
Body, J ;
Meunier, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :653-661
[85]   Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer [J].
Resch, A ;
Biber, E ;
Seifert, M ;
Resch, H .
ACTA ONCOLOGICA, 1998, 37 (7-8) :661-664
[86]   ASSESSMENT OF THE RISK OF POSTMENOPAUSAL OSTEOPOROSIS USING CLINICAL FACTORS [J].
RIBOT, C ;
POUILLES, JM ;
BONNEAU, M ;
TREMOLLIERES, F .
CLINICAL ENDOCRINOLOGY, 1992, 36 (03) :225-228
[87]   SALMON-CALCITONIN REDUCES VERTEBRAL FRACTURE RATE IN POSTMENOPAUSAL CRUSH FRACTURE SYNDROME [J].
RICO, H ;
HERNANDEZ, ER ;
REVILLA, M ;
GOMEZCASTRESANA, F .
BONE AND MINERAL, 1992, 16 (02) :131-138
[88]  
RIGGS BL, 1992, NEW ENGL J MED, V327, P620
[89]   Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study [J].
Ringe, JD ;
Faber, H ;
Dorst, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (11) :5252-5255
[90]   Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate [J].
Rittmaster, RS ;
Bolognese, M ;
Ettinger, MP ;
Hanley, DA ;
Hodsman, AB ;
Kendler, DL ;
Rosen, CJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (06) :2129-2134